{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-24-000708","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:18.047260+00:00","generated_at":"2026-06-03T04:13:18.445142+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexaria exercises warrants for ~$4.4M, issues new warrants with $4.75 strike","bullets":["Existing investor exercises 2,917,032 warrants for ~$4.4M; gross proceeds ~$4.7M including new warrant consideration.","New warrants for 2,917,032 shares at $4.75 strike, expiring Feb 2029; $0.125/share consideration paid.","Company to file resale registration statement within 60 days for new warrant shares.","H.C. Wainwright earns 6% tail fee on proceeds and receives 102,097 warrants at $5.9375.","New warrants include 9.99% beneficial ownership limitation."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-24-000708","json":"https://secwatch.observer/filing/0001640334-24-000708.json","markdown":"https://secwatch.observer/filing/0001640334-24-000708.md","text":"https://secwatch.observer/filing/0001640334-24-000708.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000708/0001640334-24-000708-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000708/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T04:13:18.445142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"56c226db48010cc15fddb4da3944999697594e5c","claim":"Lexaria Bioscience Corp. entered into Warrant Exercise Agreement with an existing accredited investor valued at approximately $4.7 million (effective 2024-04-30).","evidence_excerpt":"On April 30, 2024, Lexaria Bioscience Corp. (the “Company”) entered into a warrant exercise agreement (the “Warrant Exercise Agreement”) with an existing accredited investor (the “Investor”) to exercise in full an outstanding Common Stock Purchase Warrant (the “Exercise”) to purchase up to an aggregate of 2,917,032 shares of the Company’s common stock (the “Existing Warrant”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1348362/000164033424000708/0001640334-24-000708-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"an existing accredited investor"},{"label":"Value","value":"approximately $4.7 million"},{"label":"Effective","value":"2024-04-30"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}